SGMO Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of -95.02%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 513.09%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 419.77%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.407, which suggesting that the stock is 40.72% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, suggesting its more volatile than the S&P 500 by 110.246%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.00x versus 2.17x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of -287.29%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Novavax, Inc.'s return on equity of --.

Sangamo Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 513.09%. On the other hand Novavax, Inc. has an analysts' consensus of $12.67 which suggests that it could grow by 84.65%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Novavax, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Novavax, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.407, which suggesting that the stock is 40.72% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.00x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of 21.32%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Pfizer Inc.'s return on equity of 10.84%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 513.09%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Pfizer Inc..

Sangamo Therapeutics, Inc. has a beta of 1.407, which suggesting that the stock is 40.72% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.00x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -6012.05% compared to Sangamo Therapeutics, Inc.'s net margin of 13.19%. Sangamo Therapeutics, Inc.'s return on equity of -587.71% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Sangamo Therapeutics, Inc. has a consensus price target of $3.25, signalling upside risk potential of 513.09%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Sangamo Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Sangamo Therapeutics, Inc..

Sangamo Therapeutics, Inc. has a beta of 1.407, which suggesting that the stock is 40.72% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Sangamo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Sangamo Therapeutics, Inc. quarterly revenues are $581K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Sangamo Therapeutics, Inc.'s net income of -$34.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Sangamo Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics, Inc. is 4.00x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.